| Document |
Document Title |
|
WO/2021/179087A1 |
The present disclosure relates to a composition comprising: i) terpenes in a diamond construction for delivering a specific aroma profile; and ii) optionally, at least one cannabinoid. The present disclosure also relates to methods of us...
|
|
WO/2021/176213A1 |
A method for preparing a compound comprising a cyclopentadienyl moiety is described. The method comprises: (a) deprotonating a cyclopentadienyl moiety in a solution comprising an alkali hydroxide and a reducing agent; and (b) reacting th...
|
|
WO/2021/178841A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and comp...
|
|
WO/2021/167987A1 |
The present application is related to an improved process for synthesising 1 -(difluoromethyl)-3-iodobicyclo[1.1.1 ]pentane from difluoromethyl iodide and [1.1.1]propellane. Difluoromethyl iodide is made by reacting an iodide salt with c...
|
|
WO/2021/164850A1 |
The invention relates to a method for producing limonene comprising or consisting of the following steps: (a) providing beta-pinene or a beta-pinene containing starting material; (b) admixing the starting material with a catalytically ef...
|
|
WO/2021/164852A1 |
The invention relates to a continuous process for preparing limonene, characterized by isomeriizing beta-pinene or beta-pinene-containing reactants in the presence of acidic catalysts in a trickle be reactor.
|
|
WO/2021/161672A1 |
A silane-containing compound having a cyclic structure within the molecular structure; a modified hydrogenated petroleum resin in which the bromine value, the silicon element content, the weight-average molecular weight, and the molecula...
|
|
WO/2021/161327A1 |
The present disclosure provides a process for preparing a reforming catalyst, said process comprising: (a) impregnating at least one support with at least one promoter metal and at least one active metallic component to obtain a second c...
|
|
WO/2021/141382A1 |
The present specification relates to a fluorene-based compound of chemical formula (1), a coating composition comprising the fluorene-based compound of chemical formula (1), an organic light-emitting device using same, and a manufacturin...
|
|
WO/2021/135183A1 |
The present application relates to the technical field of organic materials, and provides an organic compound. A novel compound for an organic electroluminescent device is obtained by bonding and combining an adamantane spiro fluorenyl g...
|
|
WO/2021/132239A1 |
Provided is a method for stably producing indene over a long time with a high yield using a zeolite catalyst, as a novel method for producing indene. This method for producing indene comprises a dehydrogenation step of bringing a raw m...
|
|
WO/2021/120767A1 |
The present application provides belt[n]arene[n]tropilidene, a belt[4]arene[4]tropylium compound, a belt[4]arene[4-m]tropilidene[m]dicarbonyl compound, a belt[4]arene[4-m]tropilidene[m]benzotropilidene compound, a belt[4]arene[4-m]benzot...
|
|
WO/2021/122472A1 |
The presently claimed invention is directed to a polyurea copolymer obtained by reacting an isocyanate mixture and at least one at least one secondary amine having at least two amine functionalities; wherein the isocyanate mixture (A) ha...
|
|
WO/2021/121135A1 |
Disclosed in the present invention are a photoinitiator, a preparation method therefor and an application thereof, and a photocurable composition. The photoinitiator has the structure represented by formula (I). The photoinitiator of the...
|
|
WO/2021/119521A1 |
Embodiments of the disclosure provide a system and method for producing a linear alpha olefin. A disulfide, a hydrogen donating compound, and water are combined to produce a mixture. The mixture is introduced to a reactor operated at a p...
|
|
WO/2021/110418A1 |
The present invention relates to a method for producing a transition metal catalyst supported by means of nitrogen-doped carbon, comprising the steps: a) producing a nitrogen-doped carbon, comprising the steps: i) providing a composition...
|
|
WO/2021/109819A1 |
Provided are a polysubstituted spirobifluorenyl compound, hole transport material composition, and optoelectronic device. The structural formula I of the polysubstituted spirobifluorenyl compound is as follows, wherein R1 and R2 are sele...
|
|
WO/2021/110741A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to organic electroluminescent devices which comprise these compounds.
|
|
WO/2021/103060A1 |
Disclosed are a hole transport material, a preparation method therefor, and an organic light emitting device, the hole transport material comprising a compound having a chemical structure represented by formula I, Z comprising a carbon a...
|
|
WO/2021/102361A1 |
Disclosed herein, inter alia, are compounds and methods for inhibiting Caspase 6 and the treatment of diseases, pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient and methods o...
|
|
WO/2021/089447A1 |
The present invention relates to an organic electroluminescent apparatus containing a mixture that comprises an electron-transporting host material and a hole-transporting host material, as well as to a formulation containing a mixture o...
|
|
WO/2021/075478A1 |
In the present invention, it was discovered that an amino-group-containing compound protected by protecting groups having an Fmoc skeleton can be accurately quantified by removing the protecting groups having an Fmoc skeleton from said c...
|
|
WO/2021/026479A9 |
The present disclosure provides a compound of the formula Het1-L1-Ar1-L2-G1, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, that are useful for treating a variety of conditions. In such compounds...
|
|
WO/2021/062555A1 |
Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound, wherein the one or more cannabinoids comprise tetrahydr...
|
|
WO/2021/064724A1 |
The present invention relates to protopanaxatriol (PPT)-type compounds and compositions comprising thereof useful for controlling insect infestations on plants. The present invention also relates to methods for treating, controlling and/...
|
|
WO/2021/054337A1 |
The purpose of the present invention is to provide: a composition capable of forming a film that exhibits excellent etching resistance, heat resistance and embedding properties; a resist underlayer film; a method for forming a resist und...
|
|
WO/2021/048657A1 |
Systems and methods for recovering cyclopentadiene and/or isoprene from a mixture comprising C5 hydrocarbons are disclosed. A C5 mixture comprising cyclopentadiene and/or isoprene is flowed into a dimerization unit to form dimers. The di...
|
|
WO/2021/046628A1 |
A stable medicinal cannabidiol composition for use in oral delivery, the composition comprising synthetic cannabidiol (CBD) having a purity of at least 99.8 %, preferably at least 99.9 %, together with beta-caryophyllene (BCP) which func...
|
|
WO/2021/047036A1 |
Disclosed are an enhanced system and process for preparing cyclohexene by hydrogenating benzene, and the present invention belongs to the technical field of the preparation of cyclohexene. In the enhanced system, by installing a first mi...
|
|
WO/2021/030401A1 |
Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.
|
|
WO/2021/030773A1 |
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing ...
|
|
WO/2021/022059A1 |
The subject matter described herein is directed to compounds, synergistic compositions, and methods for repelling arthropods. The compositions comprise acids, esters, aldehydes, or alcohols of pyrethroid-type compounds. The compounds, pa...
|
|
WO/2021/014422A1 |
The present invention relates to diterpene compounds of general formula (I) capable of contrasting the antibiotic-resistance mediated by the ArnT enzyme, to their use as a medicament, in particular for use as an adjuvant of an antibiotic...
|
|
WO/2021/016464A1 |
Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.
|
|
WO/2021/012478A1 |
Provided are a hydrogenation annule [12] aromatic compound and a preparation method therefor. The hydrogenation annule [12] aromatic compound is a stereoisomer of a represented compound or a compound as represented by formula (I), (I)
|
|
WO/2021/012479A1 |
Provided are a hydrogenated cyclic [8] aromatic hydrocarbon compound and a preparation method therefor. The hydrogenated cyclic [8] aromatic hydrocarbon compound is a compound as represented by formula (I) or a stereoisomer of the compou...
|
|
WO/2021/012323A1 |
An electron transport material represented by the following formula (I), a preparation method therefor, use thereof in preparing an organic electroluminescent device, an organic electroluminescent device, an electronic display device and...
|
|
WO/2021/011572A1 |
Compounds and methods are provided for the treatment of pathogenic virus infections. Compositions and methods are provided for inhibiting RNA viruses.
|
|
WO/2021/007101A1 |
The present invention provides conjugates of a first polypeptide and a second polypeptide wherein the link between the first polypeptide and the second polypeptide comprises the following moiety.
|
|
WO/2021/000248A1 |
Disclosed in the present invention are a method and an apparatus for continuous synthesis of cyclopropane compounds. The method comprises the following steps: the synthesis reaction of a diazomethane precursor is carried out continuously...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/256546A1 |
The invention disclosed herein relates to compounds, combinations, kits, and methods using same, for use in bioorthogonal release reactions. In particular, the compounds, combinations and kits of the invention can be used to achieve fast...
|
|
WO/2020/252661A1 |
A method for the continuous synthesis of propellane compounds, comprising the following steps: using 1,1-dibromo-2,2-chloromethyl cyclopropane or a derivative thereof as a raw material, preparing propellane compounds by means of continuo...
|
|
WO/2020/251346A1 |
The present invention describes a naturally occurring chemical compound, specifically guayalins A, B, C and D used in medicine having null cytotoxicity and genotoxicity on healthy lymphocyte cells. Said active compounds interfere with th...
|
|
WO/2020/247561A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: Formula (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of ...
|
|
WO/2020/232530A1 |
There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.
|
|
WO/2020/234650A1 |
A composition comprising an active composition made up of at least 5% CBD, at least 2% β-caryophyllene, and at least 2% linalool; wherein said composition comprises a carrier and excipients to increase oral bioavailability for mammalian...
|
|
WO/2020/223811A1 |
Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or...
|
|
WO/2020/227097A1 |
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
|
|
WO/2020/219774A1 |
Antibody-drug conjugates (ADCs) comprising an anthracycline and an anti-CD117 antibody are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patien...
|
